Navigation and service

You are here:Rote-Hand-Briefe and Information Letters

Dear Doctor Letter (Rote-Hand-Brief) on hydroxyethyl starch (HES) solutions for infusion: new measures to reinforce existing restrictions due to increased risk of renal dysfunction and mortality in critically ill or septic patients

Date 2018.08.13
Active substance hydroxyethyl stark, HES

The marketing authorisation holders inform that hydroxyethyl starch (HES)-containing solutions for infusion have continued to be used in patients with contraindications. Such contraindicated use is associated with a risk for serious harm, including increased mortality.

A new programme for controlled access of hydroxyethyl starch (HES) containing medicines for infusion will be implemented.

For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):

Hydroxyethyl starch (HES) containing medicinal products